186 related articles for article (PubMed ID: 11115564)
21. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
[TBL] [Abstract][Full Text] [Related]
22. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B
Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
[No Abstract] [Full Text] [Related]
23. Sequential high dose-density chemotherapy in advanced ovarian cancer.
Tognoni A; Pronzato P; Cadenotti L; Ghio E; Manna N; Pensa F; Marino L
Anticancer Res; 2000; 20(5C):3957-61. PubMed ID: 11268483
[TBL] [Abstract][Full Text] [Related]
24. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
25. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
26. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of chemotherapy for clear cell adenocarcinoma of the ovary].
Okubo T; Takeda S; Ikeba K; Takagi Y; Ishihara O; Seki H; Kinoshita K
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1279-83. PubMed ID: 9279347
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
30. [A retrospective study of advanced ovarian cancer in our ward].
Baba T; Utsunomiya Y; Tamai A; Ueda M; Goto M; Nonogaki T
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2071-5. PubMed ID: 14712767
[TBL] [Abstract][Full Text] [Related]
31. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Misawa A; Yasuda M
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
[TBL] [Abstract][Full Text] [Related]
32. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
[TBL] [Abstract][Full Text] [Related]
33. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
[TBL] [Abstract][Full Text] [Related]
34. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
35. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
36. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
[TBL] [Abstract][Full Text] [Related]
37. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
Muggia FM; Jeffers S; Muderspach L; Roman L; Rosales R; Groshen S; Safra T; Morrow CP
Gynecol Oncol; 1997 Aug; 66(2):290-4. PubMed ID: 9264578
[TBL] [Abstract][Full Text] [Related]
39. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S
Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769
[TBL] [Abstract][Full Text] [Related]
40. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]